Studying the post-COVID-19 condition: research challenges, strategies, and importance of Core Outcome Set development.
COVID-19
COVID-19 sequalae
Core Outcome Set
Long COVID
Outcomes
PASC
Post-COVID-19 condition
Post-acute sequelae of SARS-CoV-2 infection
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
04 02 2022
04 02 2022
Historique:
received:
19
10
2021
accepted:
20
12
2021
entrez:
4
2
2022
pubmed:
5
2
2022
medline:
9
2
2022
Statut:
epublish
Résumé
A substantial portion of people with COVID-19 subsequently experience lasting symptoms including fatigue, shortness of breath, and neurological complaints such as cognitive dysfunction many months after acute infection. Emerging evidence suggests that this condition, commonly referred to as long COVID but also known as post-acute sequelae of SARS-CoV-2 infection (PASC) or post-COVID-19 condition, could become a significant global health burden. While the number of studies investigating the post-COVID-19 condition is increasing, there is no agreement on how this new disease should be defined and diagnosed in clinical practice and what relevant outcomes to measure. There is an urgent need to optimise and standardise outcome measures for this important patient group both for clinical services and for research and to allow comparing and pooling of data. A Core Outcome Set for post-COVID-19 condition should be developed in the shortest time frame possible, for improvement in data quality, harmonisation, and comparability between different geographical locations. We call for a global initiative, involving all relevant partners, including, but not limited to, healthcare professionals, researchers, methodologists, patients, and caregivers. We urge coordinated actions aiming to develop a Core Outcome Set (COS) for post-COVID-19 condition in both the adult and paediatric populations.
Sections du résumé
BACKGROUND
A substantial portion of people with COVID-19 subsequently experience lasting symptoms including fatigue, shortness of breath, and neurological complaints such as cognitive dysfunction many months after acute infection. Emerging evidence suggests that this condition, commonly referred to as long COVID but also known as post-acute sequelae of SARS-CoV-2 infection (PASC) or post-COVID-19 condition, could become a significant global health burden.
MAIN TEXT
While the number of studies investigating the post-COVID-19 condition is increasing, there is no agreement on how this new disease should be defined and diagnosed in clinical practice and what relevant outcomes to measure. There is an urgent need to optimise and standardise outcome measures for this important patient group both for clinical services and for research and to allow comparing and pooling of data.
CONCLUSIONS
A Core Outcome Set for post-COVID-19 condition should be developed in the shortest time frame possible, for improvement in data quality, harmonisation, and comparability between different geographical locations. We call for a global initiative, involving all relevant partners, including, but not limited to, healthcare professionals, researchers, methodologists, patients, and caregivers. We urge coordinated actions aiming to develop a Core Outcome Set (COS) for post-COVID-19 condition in both the adult and paediatric populations.
Identifiants
pubmed: 35114994
doi: 10.1186/s12916-021-02222-y
pii: 10.1186/s12916-021-02222-y
pmc: PMC8813480
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
50Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Organisme : Medical Research Council
ID : MC_PC_19026
Pays : United Kingdom
Informations de copyright
© 2022. The Author(s).
Références
Nat Med. 2021 Apr;27(4):626-631
pubmed: 33692530
Anesth Analg. 2020 Jul;131(1):86-92
pubmed: 32243287
BMJ. 2021 Mar 31;372:n693
pubmed: 33789877
Am J Respir Crit Care Med. 2017 Nov 1;196(9):1122-1130
pubmed: 28537429
JAMA Pediatr. 2021 Nov 1;175(11):1095-1096
pubmed: 34338711
BMJ Glob Health. 2021 Sep;6(9):
pubmed: 34580069
PLoS Med. 2021 Sep 28;18(9):e1003773
pubmed: 34582441
Clin Infect Dis. 2021 Jul 15;73(Suppl 1):S5-S16
pubmed: 33909072
Nature. 2021 Nov;599(7886):546-548
pubmed: 34815580
Sci Rep. 2021 Jul 7;11(1):14042
pubmed: 34234251
Lancet. 2020 Dec 12;396(10266):1861
pubmed: 33308453
J Invest Dermatol. 2015 Jan;135(1):24-30
pubmed: 25186228
Eur Respir J. 2022 Feb 3;59(2):
pubmed: 34210789
J Infect Dis. 2021 Dec 1;224(11):1839-1848
pubmed: 34677601
Infect Agent Cancer. 2021 Oct 30;16(1):62
pubmed: 34717691
Clin Exp Allergy. 2021 Sep;51(9):1107-1120
pubmed: 34351016
Ann Am Thorac Soc. 2021 Jun;18(6):997-1003
pubmed: 33413026
Crit Care Med. 2020 Nov;48(11):1622-1635
pubmed: 32804792
Lancet Psychiatry. 2021 May;8(5):356-359
pubmed: 33609450
Lancet. 2021 Jan 16;397(10270):220-232
pubmed: 33428867
Lancet. 2021 Aug 28;398(10302):725
pubmed: 34454656
Ann Am Thorac Soc. 2021 Jul;18(7):1253-1255
pubmed: 33472019
EClinicalMedicine. 2021 Jan 07;31:100683
pubmed: 33490928
Lancet Infect Dis. 2021 Dec 21;:
pubmed: 34951953
Crit Care Med. 2021 Mar 1;49(3):503-516
pubmed: 33400475
Ann Intern Med. 2021 Jul;174(7):999-1003
pubmed: 33780290
Acta Paediatr. 2021 Jul;110(7):2208-2211
pubmed: 33835507
J Neurol. 2021 Dec;268(12):4915-4917
pubmed: 34674007
J Med Internet Res. 2020 Sep 11;22(9):e20955
pubmed: 32788143
Nat Med. 2020 Dec;26(12):1803
pubmed: 33288947
Lancet. 2021 Aug 28;398(10302):747-758
pubmed: 34454673
Ann Intern Med. 2021 Sep;174(9):1334-1336
pubmed: 34029484
JAMA Pediatr. 2021 Aug 1;175(8):817-826
pubmed: 33885740
Lancet Reg Health Eur. 2021 Sep;8:100186
pubmed: 34386785
BMJ. 2021 Feb 10;372:n405
pubmed: 33568362
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120